SCHEMBL1256168

SCHEMBL1256168

Brc1cnc(NC2CCOCC2)nc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 8/20 0.69
HDAC3 O15379 2/20 0.62
HDAC1 Q13547 2/20 0.62
HDAC2 Q92769 2/20 0.62
HDAC6 Q9UBN7 2/20 0.62
MAPK8 P45983 1/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43
AOC3 Q16853 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
KCNH2 Q12809 1/20 0.39
MAPK3 P27361 1/20 0.39
PIK3C3 Q8NEB9 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
KDM1A O60341 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
P2RX3 P56373 1/20 0.38
P2RX2 Q9UBL9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31547075 0.89 MAPK1 (0.56) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL12237655 0.89 MAPK1 (0.56) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL248829 0.86 MAPK1 (0.48) MAPK1HDAC3HDAC1HDAC2HDAC6
Hydrochloric Acid SCHEMBL1669811 0.84 MAPK1 (0.47) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL12237657 0.82 KDM4E (0.59) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL10187962 0.82 KDM4E (0.53) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL19144932 0.81 MAPK1 (1.00) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL29730384 0.81 MAPK1 (1.00) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL25956108 0.81 KDM4E (0.62) MAPK1HDAC3HDAC1HDAC2HDAC6
SCHEMBL2568620 0.79 MAPK1 (1.00) MAPK1HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 US disclosed
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2021-04-06 US disclosed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 US disclosed
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC (US) 2020-11-05 US disclosed
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2020-09-08 US disclosed
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2020-09-08 US disclosed
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2019-10-01 US disclosed
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN, LLC (US) 2019-10-01 US disclosed
EP-2970260-B1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LLC (US) 2019-04-24 EP disclosed
EP-2970260-B1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LLC (US) 2019-04-24 EP disclosed
US-9676769-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED (GB) 2017-06-13 US disclosed
US-9676769-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PROXIMAGEN LIMITED (GB) 2017-06-13 US disclosed
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN, LLC 2016-02-18 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed
US-20150258101-A1 NEW COMPOUNDS PROXIMAGEN LIMITED (GB) 2015-09-17 US disclosed
WO-2014140592-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PROXIMAGEN LIMITED (GB) 2014-09-18 WO disclosed
US-20130035326-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-02-07 US disclosed
EP-2467137-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2012-06-27 EP disclosed
WO-2011022473-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766897-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, SSB, XDH MAPK1 2405/4885HDAC3 1948/4885HDAC1 699/4885
US-10428066-B2 Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors PNPO, SSB, XDH MAPK1 2405/4885HDAC3 1948/4885HDAC1 699/4885
US-10968223-B2 Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors PNPO, PPOX, SCO2 MAPK1 1097/4885HDAC3 2167/4885HDAC1 1019/4885
US-20200347059-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, PPOX, SCO2 MAPK1 1097/4885HDAC3 2167/4885HDAC1 1019/4885
US-20160046622-A1 IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS PNPO, AOC3, IL4I1 MAPK1 646/4885HDAC3 1649/4885HDAC1 270/4885
US-20130035326-A1 BIARYL COMPOUNDS AND METHODS OF USE THEREOF FLT3, CSF3R, CSF1R MAPK1 1682/4885HDAC3 1134/4885HDAC1 1154/4885
US-20150258101-A1 NEW COMPOUNDS AOX1, QSOX1, MAOB MAPK1 4075/4885HDAC3 1827/4885HDAC1 562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.